Comparative Pharmacology
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus NOXAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus NOXAFIL.
BUTENAFINE HYDROCHLORIDE vs NOXAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
Posaconazole oral suspension: 200 mg (5 mL) three times daily with food. Oral delayed-release tablets: 300 mg twice daily on day 1, then 300 mg once daily thereafter with food. IV: 300 mg twice daily on day 1, then 300 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life is approximately 25-30 hours (range 20-66 hours) in healthy subjects; in patients with hepatic impairment or critical illness, half-life may be prolonged up to 40-50 hours; supports once-daily dosing in most patients.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Primarily hepatic metabolism (glucuronidation) with extensive enterohepatic recirculation; renal excretion accounts for <1% as unchanged drug; approximately 71% of a radiolabeled dose is eliminated in feces (as parent drug and metabolites) and 13% in urine (as metabolites).
Category C
Category C
Antifungal
Antifungal